Neurology Devices Market to Grow at 7.46% CAGR Through 2030: Rising Alzheimer's, Parkinson's, and Dementia Cases Propel Global Expansion | DelveInsight

Neurology devices market to grow at a 7.46% CAGR through 2030, fueled by rising neurological disease prevalence, aging populations, and AI-driven innovations by key companies include Abbott (NYSE: ABT), B. Braun, Boston Scientific (NYSE: BSX), Integra LifeSciences (NASDAQ: IART), LivaNova (NASDAQ: LIVN), Medtronic (NYSE: MDT), Penumbra (NYSE: PEN), Stryker (NYSE: SYK), Philips (AMS: PHIA), MicroPort, Helius (NASDAQ: HSDT), Cerus Endovascular, Magstim TMS, Rapid Medical, and Acandis GmbH.
DelveInsight's "Neurology Devices Market Insights, Competitive Landscape, and Market Forecast - 2030 [https://www.delveinsight.com/report-store/neurology-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers a comprehensive analysis of the Neurology Devices market, covering historical and forecasted potential patient pools, competitive landscape and market outlook across the globe through 2030.

Key Takeaways

*
Market size projection: As per DelveInsight's analysis, the global neurology devices market is estimated to grow at a CAGR of 7.46% during the forecast period from 2024 to 2030, driven by increasing prevalence of neurological conditions and technological advancements.

*
Patient population data: The report highlights significant patient populations requiring neurological intervention, including over 55 million people worldwide living with dementia according to DelveInsight data.

*
Key companies: Leading neurology devices companies include Abbott (NYSE: ABT), B. Braun SE, Boston Scientific Corporation (NYSE: BSX), Integra LifeSciences (NASDAQ: IART), LivaNova plc (NASDAQ: LIVN), Medtronic (NYSE: MDT), Magstim TMS, Penumbra Inc. (NYSE: PEN), Stryker (NYSE: SYK), MicroPort Scientific Corporation (Hong Kong Stock Exchange: 0853.HK), Koninklijke Philips N.V. (Euronext Amsterdam: PHIA; ADR: PHG), Rapid Medical, Acandis GmbH, Helius Medical Technologies (NASDAQ: HSDT), and Cerus Endovascular Inc., among others.

*
The FDA continues to expand its list of AI-enabled medical devices, with several recent approvals having neurological applications. Notable recent clearances include the Swoop Portable MR Imaging System (K251276) approved in May 2025, which represents a significant advancement in portable neuroimaging technology.

*
The most significant recent FDA approval occurred in February 2025, when the agency approved Supernus Pharmaceuticals' SPN-830 (Onapgo) as the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease.

*
Several promising medtech startups are advancing innovative neurological devices in 2025, such as Inbrain Neuroelectronics, Precisis (Easee System), and Axorus.

*
The report segments the neurology devices market as neurostimulation devices, neurosurgery devices, cerebrospinal fluid management devices, and interventional neurology devices, with neurostimulation devices expected to maintain a significant market share due to their effectiveness in treating neuropathic pain and spinal injuries.

Recent tariff measures enacted in 2025 have introduced a baseline 10% duty on most Chinese imports affecting Neurology Devices supply chains, with derivative tariffs of 25% on steel and aluminum components taking effect in March 2025. Know more about how the companies are navigating these tariff tensions @ Neurology Devices Recent Developments [https://www.delveinsight.com/sample-request/neurology-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Neurology Devices Market Dynamics

The global neurology devices market demonstrates strong momentum driven by multiple convergent factors that collectively create a favorable growth environment. The current neurology devices market landscape is characterized by increasing regulatory approvals across various neurology device categories, establishing a foundation for sustained expansion through 2030.

The neurology devices market is primarily fueled by the escalating prevalence of hard-to-treat neurological diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and multiple sclerosis. The demographic shift toward an aging global population serves as a fundamental growth driver, with the World Health Organization projecting that by 2030, at least one in six people will be aged 60 years or above, increasing to 2.1 billion by 2050. This demographic transformation directly correlates with increased susceptibility to neurological conditions such as dementia, stroke, and other age-related neurological disorders.

The scientific rationale underlying neurology devices centers on their ability to target specific deep subcortical, cortical, spinal, cranial, and peripheral nerve structures to modify or modulate neuronal activity. Neurostimulation devices, representing a significant market segment, provide therapeutic effects for numerous neurological diseases, including chronic pain, movement disorders, epilepsy, and Parkinson's disease, through precise neural pathway modulation.

The neurology devices clinical development activity reflects robust pipeline engagement across the industry, with companies focusing on enhancing device safety, affordability, and usability for end users. The increasing frequency of head injuries from accidents and workplace incidents further drives demand for various neurological devices, creating sustained market expansion opportunities.

The neurology device competitive landscape demonstrates significant industry participation with established players investing in technological advancement and regulatory compliance. Strategic approaches include focusing on product innovation, expanding geographical presence, and developing comprehensive device portfolios to address diverse neurological conditions.

However, the market faces challenges, including high costs and risks associated with various neurology devices, which may constrain adoption rates in price-sensitive markets. The COVID-19 pandemic initially impacted market growth through healthcare system disruptions, but recovery has been facilitated by vaccine development and the resumption of regular healthcare services.

The future neurology devices market outlook indicates sustained growth driven by continued demographic aging, increasing neurological disease prevalence, technological innovation, and expanding regulatory approvals. The market is expected to benefit from ongoing research and development initiatives aimed at developing more effective and accessible neurological treatment solutions.

Download the Neurology Devices Market report to understand which factors are driving the therapeutic market @ Neurology Devices Market Trends [https://www.delveinsight.com/sample-request/neurology-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Neurology Devices Targeted Patient Pool

The neurology devices patient pool reflects a substantial and growing patient population across multiple neurological conditions, with particular concentration in developed markets. The global burden of neurological diseases demonstrates significant variation across geographic regions, with North America showing particularly high incidence rates that drive device utilization. According to the American Society for Biochemistry and Molecular Biology data from 2021, brain injuries occur every nine seconds in the United States, resulting in more than 3.5 million incidents annually, with approximately 3 million people suffering from traumatic brain injury each year, of which 280K result in hospitalizations.

The neurology devices patient pool segmentation reveals distinct patterns across different neurological conditions, with Parkinson's disease affecting approximately 60K newly diagnosed patients annually in America, according to the Parkinson's Foundation. Brain and central nervous system cancers contribute to additional patient populations, with GLOBOCAN 2020 recording approximately 25K cases in the United States alone. Alzheimer's disease represents a particularly significant epidemiological burden, with the Alzheimer's Association reporting that more than 6 million Americans currently live with the condition, projected to increase to nearly 13 million by 2050.

The total eligible patient pool encompasses individuals across various neurological conditions requiring device-based interventions, including those with movement disorders, chronic pain conditions, epilepsy, and neurodegenerative diseases. Treatment patterns indicate that device utilization correlates strongly with disease severity and available healthcare infrastructure, with treated case volumes reflecting both clinical need and healthcare system capacity.

Furthermore, geographic segmentation demonstrates North America's dominance in both disease prevalence and device utilization, attributed to advanced healthcare infrastructure, higher diagnostic rates, and greater access to specialized neurological care. The forecast period through 2030 anticipates continued growth in diagnosed cases due to improved diagnostic capabilities, increased healthcare awareness, and demographic aging trends across major markets.

Discover evolving trends in the Neurology Devices patient pool forecasts @ Neurology Devices Patient Pool Analysis. [https://www.delveinsight.com/sample-request/neurology-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Key Neurology Devices Companies and Treatment Market

The clinical and regulatory landscape for neurology devices encompasses a comprehensive ecosystem of established medical device manufacturers and emerging technology companies focused on neurological applications. Current treatment options span multiple device categories, including neurostimulation systems for pain management and movement disorders, neurosurgical instruments for interventional procedures, cerebrospinal fluid management devices for hydrocephalus and related conditions, and interventional neurology devices for stroke and vascular interventions.

The neurology devices clinical pipeline activity demonstrates robust development phases across various neurological applications, with companies pursuing regulatory approvals for next-generation devices offering enhanced precision, reduced invasiveness, and improved patient outcomes. Key neurology device manufacturers include Abbott with their neurostimulation portfolio, Boston Scientific Corporation focusing on deep brain stimulation and spinal cord stimulation systems, Medtronic maintaining leadership in comprehensive neurological device solutions, Stryker specializing in neurosurgical instruments and navigation systems, and LivaNova plc developing innovative neurostimulation therapies.

Market positioning reflects each company's strategic focus within current treatment paradigms, with established players leveraging extensive clinical evidence and regulatory experience while emerging companies introduce disruptive technologies. Abbott's neurostimulation devices target chronic pain and movement disorders through advanced programming capabilities, while Boston Scientific's systems emphasize precision targeting and patient customization. Medtronic's comprehensive portfolio spans multiple neurological conditions with integrated therapy management platforms.

The competitive environment emphasizes technological differentiation through mechanisms of action improvements, clinical application expansion, and development status advancement across various pipeline programs. Companies pursue strategic partnerships and licensing arrangements to accelerate development timelines and expand market access, with particular focus on addressing unmet clinical needs in neurological care.

Delve deeper into the major and specialised companies in the Neurology Devices market @ Neurology Devices Competitive Landscape [https://www.delveinsight.com/sample-request/neurology-devices-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Conclusion

DelveInsight's comprehensive analysis reveals a neurology devices market positioned for substantial growth through 2030, driven by demographic aging, increasing neurological disease prevalence, and continuous technological innovation. The 7.46% CAGR projection reflects strong market fundamentals supported by robust clinical development pipelines and expanding regulatory approvals. North America's market leadership, combined with significant patient populations requiring neurological interventions, establishes a foundation for sustained industry expansion. Key market participants continue investing in advanced technologies while addressing cost and accessibility challenges, positioning the neurology devices sector for a long-term growth trajectory that aligns with evolving healthcare needs and demographic trends.

Table of Contents

1. Neurology Devices Market Report Introduction

2. Neurology Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Neurology Devices Market Key Factors Analysis

6. Neurology Devices Market Porter's Five Forces Analysis

7. Neurology Devices Market Assessment

8. Neurology Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a leading business consulting and market research company focused on the healthcare and life sciences sectors, providing comprehensive market intelligence, competitive landscape analysis, and strategic insights to support decision-making across the pharmaceutical industry.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neurology-devices-market-to-grow-at-746-cagr-through-2030-rising-alzheimers-parkinsons-and-dementia-cases-propel-global-expansion-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.